Loading
NASDAQHealthcareBiotechnology
Latest quote
$15.60
+$0.33 · +2.16%
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Latest quote
$15.60
+$0.33 · +2.16%
Regular session · ET · Market data may be delayed.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Day range
Current $15.60
52-week range
Current $15.60
Regular session · ET · Market data may be delayed.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Day range
Current $15.60
52-week range
Current $15.60
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 |
|---|---|---|
| Revenue | 1.35M USD | — |
| Cost of goods sold | 804K USD | 313K USD |
| Gross profit | 546K USD | −313K USD |
| Research and development | 54.15M USD | 33.86M USD |
| Selling, general, and administrative | 13.55M USD | 7.38M USD |
| Operating expenses | 67.71M USD | 41.24M USD |
| Interest income | 6.63M USD | 3.44M USD |
| Depreciation and amortization | 804K USD | 313K USD |
| Operating income | −67.16M USD | −41.55M USD |
| Net income | −60.63M USD | −39.8M USD |
Company facts updated Nov 4, 2026.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI9.73M0.00%689.2B USD0.03%$376.92+1.54%
Vanguard Extended Market ETFVXF3.34M0.00%30.2B USD0.05%$233.44+0.77%
Schwab U.S. Small-Cap ETFSCHA1.37M0.01%22.12B USD0.03%$33.59+1.39%
Vanguard Russell 2000 ETFVTWO305.13K0.00%16.6B USD0.06%$114.65+1.46%
Schwab U.S. Broad Market ETFSCHB172.16K0.00%44.21B USD0.03%$29.48+1.52%
Vanguard Russell 2000 Growth ETFVTWG30.54K0.00%1.4B USD0.06%$260.31+1.27%
Vanguard Russell 2000 Value ETFVTWV11.11K0.00%1.3B USD0.06%$192.85+1.77%
Vanguard Russell 3000 ETFVTHR4.51K0.00%4.9B USD0.06%$337.75+1.55%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOSchwab U.S. Broad Market ETFSCHBVanguard Russell 2000 Growth ETFVTWGVanguard Russell 2000 Value ETFVTWVVanguard Russell 3000 ETFVTHRAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
